DPYS Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q14117 |
---|---|
Clone Names | 90429114 |
Gene ID | 1807 |
---|---|
Other Names | Dihydropyrimidinase, DHP, DHPase, Dihydropyrimidine amidohydrolase, Hydantoinase, DPYS |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP13434b was selected from the C-term region of DPYS. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | DPYS |
---|---|
Function | Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyze the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate. |
Tissue Location | Liver and kidney. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Dihydropyrimidinase catalyzes the conversion of5,6-dihydrouracil to 3-ureidopropionate in pyrimidine metabolism.Dihydropyrimidinase is expressed at a high level in liver andkidney as a major 2.5-kb transcript and a minor 3.8-kb transcript.Defects in the DPYS gene are linked to dihydropyrimidinuria.
References
Kim, H.Y., et al. BMB Rep 43(8):547-553(2010)van Kuilenburg, A.B., et al. Biochim. Biophys. Acta 1802 (7-8), 639-648 (2010) :Fidlerova, J., et al. Cancer Chemother. Pharmacol. 65(4):661-669(2010)Thomas, H.R., et al. Pharmacogenet. Genomics 18(1):25-35(2008)Thomas, H.R., et al. Pharmacogenet. Genomics 17(11):973-987(2007)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.